Carbohydrate metabolism disorders and osteoporosis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Diabetes mellitus (DM) and osteoporosis are two socially significant and mutual burdened diseases that have reached the scale of epidemic. These diseases are closely related and have common pathogenetic mechanisms of development. However, problems of insufficient prevention and diagnosis of both prediabetes and osteopenic conditions remain. Timely therapy for prediabetes with metformin can have a beneficial effect on both the patient’s glycemic and metabolic status, and the state of bone tissue. When choosing a hypoglycemic therapy, it should be taking into account that drugs can have both a negative effect on the state of bone tissue (insulin, thiazilidones, sulfonylureas), and neutral (glucagon-like peptide-1 receptor agonists) or a positive effect (metformin, dipeptidyl peptidase-4 inhibitors).

全文:

受限制的访问

作者简介

Natalya Alekseeva

Novokuznetsk State Institute for Advanced Training of Doctors - Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: natali-sim82@mail.ru
Dr. Sci. (Med.), Associate Professor, Head of the Department of General Medical Practice (Family Doctor) Novokuznetsk, Russia

参考

  1. Дедов И.И, Шестакова М.Д., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-
  2. Вербовой А.Ф., Пашенцева А.В., Шаронова Л.А. Остеопороз: современное состояние проблемы. Терапевтический архив. 2017;89(5):90-7.
  3. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск. М., 2021. 288 с.
  4. Шестакова М.В., Чазова И.Е., Шестакова Е.А. Российское многоцентровое скрининговое исследование по выявлению недиагностированного сахарного диабета 2 типа у пациентов с сердечно-сосудистой патологией. Сахарный диабет. 2016;19(1):24-9.
  5. Шмелева С.В. Менопауза и частота переломов. Паллиативная медицина и реабилитация. 2012;(1):44-6.
  6. Раскина Т.А., Аверкиева Ю.В. Частота остеопо-ротических переломов бедра у лиц старшей возрастной группы г Кемерово. Современная ревматология. 2013;(1):50-3.
  7. Лесняк О.М., Баранова И.А., Белова К.Ю. Остеопороз в Российской Федерации: эпидемиология, медико-социальные и экономические аспекты проблемы (обзор литературы). Травматология и ортопедия России. 2018;24(1):155-68.
  8. Демидова Т.Ю., Кишкович Ю.С. Предиабет: современное состояние проблемы и возможности коррекции. Русский медицинский журнал (РМЖ). Медицинское обозрение. 2019;10(II):60-7.
  9. Matsushita K., Blecker S., Pazin-Filho A., et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diab. 2010;59(8):2020-26. doi: 10.2337/db10-0165.
  10. Chi C., Qi C., Bin'en N., et al. Trends in Bone Mineral Density, Osteoporosis, and Osteopenia Among U.S. Adults With Prediabetes, 2005-2014. Diab Care. 2020;43(5):1008-15. Doi: 10.2337/ dc19-1807.
  11. Ulas Serkan Topaloglu, Kemal Erol. Bone mineral density and fracture risk in prediabetes: a controlled cross-sectional study. Acta Reumatol Port. 2021;46(1):32-9.
  12. Марченкова Л.А., Макарова Е.В., Герасименко М.Ю. Распространенность остеопороза, ассоциирующихся с ним переломов и уровня информированности по проблеме среди пациентов, проходящих медицинскую реа -билитации. Лечащий врач. 2020;2:54-7.
  13. Starup-Linde J., Gregersen S., Vestergaard P. Associations with fracture in patients with diabetes: a nested casecontrol study. BMJ. Open. 2016;6(2):e009686. Doi: 10.1136/ bmjopen-2015-009686.
  14. Katayama Y, Akatsu T., Yamamoto M., et al. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Mineral Res. 1996;11(7):931-37. Doi: 10.1002/ jbmr.5650110709.
  15. Starup-Linde J., Vestergaard P Biochemical bone turnover markers in diabetes mellitus - a systematic review. Bone. 2016;82:69-78. Doi: 10.1016/j. bone.2015.02.019.
  16. Xie J., Mendez J.D., Mendez-Valenzuela V, et al. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2813;25(11):2145-97. Doi: 10.1016/j. cellsig.2013.06.013.
  17. Janghorbani M., Dam R.M., Willett W.C., et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166)5):495-505. doi: 10.1093/aje/kwm106.
  18. Liefde I., M. Klift M., Laet C.E.D., et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteopor Int. 2005;16 (12):1713-20. doi: 18.1887/s88194- 005-1909-1.
  19. Dhaliwal R., Cibula D., Ghosh C., et al. Bone quality assessment in type 2 diabetes mellitus. Osteopor Int. 2014;25(7):1969-73. Doi: 10.1007/ s00198-014-2704-7.
  20. Cai Z.Y, Yang B., Shi Y.X., et al. High glucose downregulates the effects of autophagy on osteoclastogenesis via the AMPK/mTOR/ULK1 pathway. Biochem Biophys Res Communicat. 2018;503(2):428-35. Doi: 10.1016/j. bbrc.2018.04.052.
  21. Xie J., Mendez J.D., Mendez-Valenzuela V, et al. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2813;25(11):2145-97. Doi: 10.1016/j. cellsig.2013.06.013.
  22. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011;12(14):2096-102. doi: 10.2174/138945011798829456.
  23. Graves D.T., Kayal R.A. Diabetic complications and dysregulated innate immunity. Front Biosci. 2008;13(13):1227-39. doi: 10.2741/2757.
  24. Ducy P, Amling M., Takeda S., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197-207.
  25. Takeda S., Elefteriou F, vasseur R., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305-17.
  26. Richards B., Valdes A. M., Burling K., et al. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007;92(4):1517-23. doi: 10.1210/jc.2006-2097.
  27. Yamada C., Yamada Y, Tsukiyama K., et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinol. 2008;149(2):574- 79. doi: 18.1218/en.2887-1292.
  28. Glorie L., D'Haese PC., Verhulst A. Boning up on DPP4, DPP4 substrates, and DPP4-adipokine interactions: Logical reasoning and known facts about bone related effects of DPP4 inhibitors. Bone. 2016;92:37-49. Doi: 10.1016/j. bone.2016.08.009.
  29. Rubin M.R. Bone cells and bone turnover in diabetes mellitus. Curr Osteopor Rep. 2015;13(3):186-91. doi: 10.1007/s11914-015-0265-0.
  30. Zhang Q, Riddle R.C., Clemens T.L. Bone and the regulation of global energy balance. J Intern Med. 2810;277)6):641-49. Doi: 18.1111/ joim.12348.
  31. Palomer X., Gonzalez-Clemente J.M., Blanco-Vaca F, et al. Role of vitamin in the pathogenesis of type 2 diabetes mellitus. Diab Obes Metab. 2008;10(3):185-97. doi: 10.1111/j.1463-1326.2007.00710.x.
  32. Gupte A.A, Pownall H.J., Hamilton D.J. Estrogen: an emerging regulator of insulin action and mitochondrial function. J Diab Res. 2015;2015(Article ID 916585):9.
  33. Vestergaard P., Rejnmark L., Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int. Doi: 18.1887/ s00223-008-9195-5.
  34. Lecka-Czernik B. Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs. 2009;10:1085-90.
  35. Janghorbani M., Van Dam R.M., Willett W.C., et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2887;166:490-080. Doi: 18.1893/ aje/kwm186.
  36. Garcia-Martin A., Rozas-Moreno P, Reyes-Garcia R., et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2811;97:234-41. doi: 10.1210/jc.2011-2186.
  37. Schwartz A.V, Sellmeyer D.E., Ensrud K.E., et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2881;46:32-4. Doi: 18.1218/ jcem.86.1.7139.
  38. SchwartzA.V, Hillier T.A., Sellmeyer D.E., et al. Older women with diabetes have a higher risk of falls: a prospective study. Diab Care. 2002;25:1749-54. doi: 10.2337/diacare.25.10.1749
  39. Melton L.J., Leibson C.L., Achenbach S.J., et al. Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study. J Bone Miner Res. 2884;23:1334-42. Doi: 18.1359/ jbmr.080323
  40. Rajpathak S.N., Fu C., Brodovicz K.G., et al. Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes. Drugs Aging. 2015;32(4):321-27. doi: 10.1007/s40266-015-0254-0.
  41. Kahn S.E., HaffnerS.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43. doi: 10.1056/NEJMoa066224.
  42. Kahn S.E., Zinman B., Lachin J.M., et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diab. Care. 2008;31:845-51.
  43. Dormuth C.R., Carney G., Carleton B., et al. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2889;169:1395-482. doi: 10.1001/archinternmed.2009.214.
  44. Douglas I.J., Evans S.J., Pocock S., et al. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6:e1000154. doi: 10.1371/journal. pmed.1000154.
  45. Jang W.G., Kim E.J., Bae I.H., et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone. 2011;48:885-93. Doi: 10.1016/j. bone.2010.12.003.
  46. Mai Q.G., Zhang Z.M., Xu S., et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2811;112:2982-989. doi: 10.1002/jcb.23206.
  47. Borges J.L., Bilezikian J.P, Jones-leone A.R., et al. A randomized, parallel group, doubleblind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/ metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diab Obes Metab. 2011;13:1036-46. doi: 10.1111/j.1463-1326. 2011.01461.x.
  48. Sedlinsky C., Molinuevo M.S., Cortizo A.M., et al. Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats. Eur J Pharmacol. 2011;668:477-85. Doi: 10.1016/j. ejphar.2011.07.033.
  49. Bunck M.C., Eliasson B., Corner A., et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diab Obes Metab. 2811;13:374- 77. doi: 10.1111/j.1463-1326.2010.01355.x.
  50. Monami M., Dicembrini I., Antenore A., et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diab Care. 2811;34:2474-76. doi: 10.2337/dc11-1099.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021
##common.cookie##